Outcomes in patients with clinical Stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site
Antineoplastic Combined Chemotherapy Protocols
Lymph Node Excision
Neoplasms, Germ Cell and Embryonal
A CCR at the ERP disease site is associated with a greater likelihood of relapse compared with a PCR, underscoring the limitations of radiographic imaging after chemotherapy in detecting microscopic residual disease and need for rigorous monitoring of patients observed after a CCR. Furthermore, until more accurate clinical predictors of ERP histologic features are identified, we advocate for complete surgical resection of all sites of residual disease, when feasible.